Indobufen treatment in type iia hypercholesterolemic subjects: Effects on platelet function and malondialdehyde production

E. Tremoli, P. Maderna, M. Sirtori, S. Colli, G. Corvi, C. R. Sirtori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.

Original languageEnglish
Pages (from-to)847-859
Number of pages13
JournalPharmacological Research Communications
Volume13
Issue number9
DOIs
Publication statusPublished - 1981

Fingerprint

Malondialdehyde
Blood Platelets
Platelet Aggregation
Platelet Aggregation Inhibitors
Therapeutics
Arachidonic Acid
Cross-Over Studies
Epinephrine
Healthy Volunteers
Placebos
indobufen
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Indobufen treatment in type iia hypercholesterolemic subjects : Effects on platelet function and malondialdehyde production. / Tremoli, E.; Maderna, P.; Sirtori, M.; Colli, S.; Corvi, G.; Sirtori, C. R.

In: Pharmacological Research Communications, Vol. 13, No. 9, 1981, p. 847-859.

Research output: Contribution to journalArticle

@article{96f680f55ad74f598638057042efc221,
title = "Indobufen treatment in type iia hypercholesterolemic subjects: Effects on platelet function and malondialdehyde production",
abstract = "Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.",
author = "E. Tremoli and P. Maderna and M. Sirtori and S. Colli and G. Corvi and Sirtori, {C. R.}",
year = "1981",
doi = "10.1016/S0031-6989(81)80045-8",
language = "English",
volume = "13",
pages = "847--859",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "9",

}

TY - JOUR

T1 - Indobufen treatment in type iia hypercholesterolemic subjects

T2 - Effects on platelet function and malondialdehyde production

AU - Tremoli, E.

AU - Maderna, P.

AU - Sirtori, M.

AU - Colli, S.

AU - Corvi, G.

AU - Sirtori, C. R.

PY - 1981

Y1 - 1981

N2 - Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.

AB - Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.

UR - http://www.scopus.com/inward/record.url?scp=0019869275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019869275&partnerID=8YFLogxK

U2 - 10.1016/S0031-6989(81)80045-8

DO - 10.1016/S0031-6989(81)80045-8

M3 - Article

C2 - 7335762

AN - SCOPUS:0019869275

VL - 13

SP - 847

EP - 859

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 9

ER -